Departamento de Atención a la Salud, CBS. Unidad Xochimilco, Universidad Autónoma Metropolitana, Calzada del Hueso 1100, Villa Quietud, Coyoacán, Ciudad de México 04960, Mexico.
Int J Mol Sci. 2023 Aug 18;24(16):12924. doi: 10.3390/ijms241612924.
Proteomics in respiratory allergic diseases has such a battery of techniques and programs that one would almost think there is nothing impossible to find, invent or mold. All the resources that we document here are involved in solving problems in allergic diseases, both diagnostic and prognostic treatment, and immunotherapy development. The main perspectives, according to this version, are in three strands and/or a lockout immunological system: (1) Blocking the diapedesis of the cells involved, (2) Modifications and blocking of paratopes and epitopes being understood by modifications to antibodies, antagonisms, or blocking them, and (3) Blocking FcεRI high-affinity receptors to prevent specific IgEs from sticking to mast cells and basophils. These tools and targets in the allergic landscape are, in our view, the prospects in the field. However, there are still many allergens to identify, including some homologies between allergens and cross-reactions, through the identification of structures and epitopes. The current vision of using proteomics for this purpose remains a constant; this is also true for the basis of diagnostic and controlled systems for immunotherapy. Ours is an open proposal to use this vision for treatment.
在呼吸过敏性疾病的蛋白质组学中有如此多的技术和方案,人们几乎会认为没有什么是不可能找到、发明或塑造的。我们在这里记录的所有资源都涉及解决过敏性疾病的问题,包括诊断和预后治疗以及免疫治疗的发展。根据这一版本,主要观点有三个方面,或一个免疫系统的封锁:(1)阻止相关细胞的穿细胞运动,(2)通过抗体的修饰、拮抗或阻断来修饰和阻断副位和表位,(3)阻断 FcεRI 高亲和力受体,以防止特异性 IgE 附着在肥大细胞和嗜碱性粒细胞上。在我们看来,这些工具和靶标是过敏领域的前景。然而,仍有许多过敏原有待识别,包括通过识别结构和表位来识别过敏原之间的某些同源性和交叉反应。目前使用蛋白质组学来实现这一目标的设想仍然是不变的;这对于免疫治疗的诊断和控制系统的基础也是如此。我们提出了一个开放的建议,即利用这一愿景进行治疗。